JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Osmatescu, Angela | |
| dc.contributor.author | Chesov, Elena | |
| dc.date.accessioned | 2020-07-10T12:52:29Z | |
| dc.date.available | 2020-07-10T12:52:29Z | |
| dc.date.issued | 2018 | |
| dc.identifier.citation | OSMATESCU, Angela, CHESOV, Elena. Additional second line TB drug resistance in high Burden MDR TB setting. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 86-87. | en_US |
| dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf | |
| dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11234 | |
| dc.description | Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova | en_US |
| dc.description.abstract | Introduction. Standard treatment regimen containing 4 second line tuberculosis drugs (SLD) is currently prescribed in multidrug resistant tuberculosis (MDR TB) patients while drug sensitivity test (DST) results are pending. However, potential additional resistance to SLD could lead to exposure of these patients to non-efficient toxic regimen during 2-4 weeks of pending period. Therefore, data on frequency of additional SDL resistance in MDR TB patients is crucial for programmatic decision on treatment policies in this group of patients. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | MedEspera | en_US |
| dc.subject | tuberculosis | en_US |
| dc.subject | DST | en_US |
| dc.subject | resistance | en_US |
| dc.subject | second line drug | en_US |
| dc.title | Additional second line TB drug resistance in high Burden MDR TB setting | en_US |
| dc.type | Article | en_US |
Files in this item
This item appears in the following Collection(s)
-
MedEspera 2018
The 7th International Medical Congress for Students and Young Doctors, May 3-5, 2018